Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 9
Submit an article Journal homepage
407
Views
26
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

Elizabeth O. HexnerAbramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
,
John MascarenhasTisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence[email protected]
,
Josef PrchalUniversity of Utah, Salt Lake City, UT, USA
,
Gail J. RobozWeill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA
,
Maria R. BaerGreenbaum Cancer Center, University of Maryland, Baltimore, MD, USA
,
Ellen K. RitchieWeill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA
,
David LeibowitzPalo Alto Medical Foundation, Palo Alto, CA, USA
,
Erin P. DemakosTisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
Crystal MillerTisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
James SiutyTisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
Jill KleczkoTisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
Leah PricePopulation Health & Environmental Medicine, New York University, New York, NY, USA
,
Grace JeschkeAbramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
,
Rona WeinbergMyeloproliferative Disorders Laboratory, New York Blood Center, New York, NY, USA
,
Titiksha BasuSection of Molecular Hematology, Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany
,
Heike L. PahlSection of Molecular Hematology, Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany
,
Attilio OraziWeill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA
,
Vesna NajfeldTisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
,
Roberto MarchioliHematology-Oncology Therapeutic Delivery Unit, Quintiles SpA, Milan, Italy
,
Judith D. GoldbergPopulation Health & Environmental Medicine, New York University, New York, NY, USA
,
Lewis R. SilvermanTisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
&
Ronald HoffmanTisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
 show all
Pages 2543-2551 | Received 13 Oct 2014, Accepted 15 Dec 2014, Published online: 20 Feb 2015

References

  • Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 2005;352:1744–1746.
  • Levis M, Tse KF, Smith BD, et al. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001;98:885–887.
  • Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002;99:3885–3891.
  • Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103: 3669–3676.
  • Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262–3270.
  • Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117:3294–3301.
  • Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701)is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111:5663–5671.
  • Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131–1136.
  • Hexner E, Roboz G, Hoffman R, et al. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. Br J Haematol 2014;164:83–93.
  • Barosi G, Bordessoule D, Briere J, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005;106:2849–2853.
  • Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497–1503.
  • Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013–1018.
  • Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703–1708.
  • Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011;25:82–88.
  • Jones WF Jr, Finland M. Blood levels from orally administered penicillins G and V; relation to food intake. N Engl J Med 1955;253: 754–761.
  • Levis M, Brown P, Smith BD, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006;108: 3477–3483.
  • Sonbol MB, Firwana B, Zarzour A, et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 2013;4:15–35.
  • Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011;118:401–408.
  • Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789–796.
  • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807.
  • Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18:521–528.
  • Kalota A, Jeschke GR, Carroll M, et al. Intrinsic resistance to JAK2 inhibition in myelofibrosis. Clin Cancer Res 2013;19:1729–1739.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.